Literature DB >> 3232172

Predominance of Leishmania braziliensis braziliensis in the regions of Três Braços and Corte de Pedra, Bahia, Brazil.

A C Rosa1, C C Cuba, A Vexenat, A C Barreto, P D Marsden.   

Abstract

Entities:  

Mesh：

Year:  1988        PMID： 3232172     DOI： 10.1016/0035-9203(88)90138-1

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


× No keyword cloud information.
  4 in total

1.  Lesion size correlates with Leishmania antigen-stimulated TNF-levels in human cutaneous leishmaniasis.

Authors:  Fabiano Oliveira; Andre Bafica; Andrea B Rosato; Cecilia B F Favali; Jackson M Costa; Virginia Cafe; Manoel Barral-Netto; Aldina Barral
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

2.  The -2518bp promoter polymorphism at CCL2/MCP1 influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil.

Authors:  Rajendranath Ramasawmy; Eliane Menezes; Andrea Magalhães; Joyce Oliveira; Léa Castellucci; Roque Almeida; Maria Elisa A Rosa; Luiz Henrique Guimarães; Marcus Lessa; Elza Noronha; Mary E Wilson; Sarra E Jamieson; Jorge Kalil; Jenefer M Blackwell; Edgar M Carvalho; Amélia Ribeiro de Jesus
Journal:  Infect Genet Evol       Date:  2010-04-27       Impact factor: 3.342

3.  Specificity of the rapid rK39 antigen-based immunochromatographic test Kalazar Detect(r) in patients with cutaneous leishmaniasis in Brazil.

Authors:  Félix Javier León Molinet; Julia Sonia Ampuero; Rodrigo Diniz Costa; Elza Ferreira Noronha; Gustavo Adolfo Sierra Romero
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-05       Impact factor: 2.743

4.  The microbiological signature of human cutaneous leishmaniasis lesions exhibits restricted bacterial diversity compared to healthy skin.

Authors:  Vanessa R Salgado; Artur T L de Queiroz; Sabri S Sanabani; Camila I de Oliveira; Edgar M Carvalho; Jackson M L Costa; Manoel Barral-Netto; Aldina Barral
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-04       Impact factor: 2.743
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.